New combo therapy aims to control advanced breast cancer
Disease control
Ongoing
This early-stage trial tests a new drug, OP-1250, combined with the approved drug palbociclib in people with advanced or metastatic HR-positive, HER2-negative breast cancer. The main goals are to find the safest dose and check for side effects. About 60 adults whose cancer has sp…
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC